Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin in 68Ga-DOTATET Positive Castrate-Resistant Prostate Cancer
NCT02631616Phase 1Unknown
- Sponsor
- Hadassah Medical Organization
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Peptides
01
Overview
Phase 1, open-label, single-arm trial of octreotide in prostate cancer (PCa), sponsored by Hadassah Medical Organization. Primary endpoint: Clinical response at 4 months. Status: unknown.
02
Drugs
octreotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02631616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02631616.